S425
Clinical - Gynaecological
ESTRO 2026
remained the only independent predictor of OS (HR = 2.9, p = 0.01). Conclusion: Beyond BMI, sarcopenic obesity identifies a vulnerable subset of patients with significantly poorer outcomes, underscoring the importance of integrating muscle mass assessment into personalized treatment strategies.Future prospective studies are warranted to investigate the impact of radiotherapy and treatment-induced changes in body composition on sarcopenia progression and patient outcomes. Keywords: Sarcopenic Obesity, Cervical cancer Nimotuzumab plus CCRT versus CCRT for locally advanced cervical squamous cell carcinoma: the randomized, phase 3 CC3 study (NCT04678791) Ping Jiang 1 , Junjie Wang 1 , Ang Qu 1 , Lichun Wei 2 , Lijuan Zou 3 , Xiaofan Li 4 , Chunyan Wang 5 , Xiaoge Sun 6 , Li Ding 7 , Xiangkun Yuan 8 , Huijun Cheng 9 , Dehua Wu 10 , Rong Cai 11 , Rutie Yin 12 , Jidong Zhang 13 , Hui Qiu 14 , Tiejun Wang 15 , Kun Gao 16 , Yanhong Zhuo 17 , Yunyan Zhang 18 1 Department of Radiation Oncology, Peking University Third Hospital, Beijing, China. Proffered Paper 1492 2 Department of Radiotherapy, The First Affiliated Hospital ， the Air Force Medical University, Xi’an, China. 3 Department of Radiation Oncology, The Second Hospital of Dalian Medical University, Dalian, China. 4 Department of Radiation Oncology, Beijing Cancer Hospital, Beijing, China. 5 Department of Gynecology, Liaoning Cancer Hospital & Institute, Shenyang, China. 6 Department of Radiotherapy, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China. 7 Department of Radiotherapy, Baotou Cancer Hospital, Baotou, China. 8 Department of Oncology Chemoradiotherapy, Cangzhou Hospital Of integrated TCM-WM•Hebei, Cangzhou, China. 9 Gynecologic Oncology,
Henan Cancer Hospital, Zhengzhou, China. 10 Department of Radiotherapy, Nanfang Hospital, Guangzhou, China. 11 Department of Radiotherapy, Ruijin Hospital ,Shanghai Jiao tong University School of Medicine, Shanghai, China. 12 Department of Oncology Chemoradiotherapy, West China Second University Hospital, Sichuan University, Chengdu, China. 13 Gynecological radiotherapy, Shanxi Province Tumor Hospital, Taiyuan, China. 14 Department of Oncology Chemoradiotherapy, Zhongnan Hospital of Wuhan University, Wuhan, China. 15 Department of Radiation Oncology, The second norman bethune hospital of jilin university, Changchun, China. 16 Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning, China. 17 Department of Radiation Oncology, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China. 18 Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China Purpose/Objective: There are few studies on targeted therapy combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). This CC3 study is the first randomized, controlled, multicenter phase 3 trial of EGFR antibody combined with CCRT for locally advanced cervical cancer (LACC), aims to evaluate the efficacy and safety of nimotuzumab (humanized EGFRmonoclonal antibody) in combination with CCRT for LACC. Material/Methods: All patients with locally advanced cervical squamous cell carcinoma were randomized (1:1) to receive nimotuzumab (400mg, iv, weekly, for 6 weeks) combined with CCRT (cisplatin: 40 mg/m2, weekly, for 6 weeks; IMRT/VMAT: 45-50.4 Gy/25-28f; high-dose rate brachytherapy: 30-40 Gy, in 8 weeks) or CCRT alone. The primary endpoint was 3-year progression free survival (PFS) per RECIST 1.1. The secondary endpoints were 3-year overall survival (OS), objective response rate (ORR),
Made with FlippingBook - Share PDF online